Navigation (Skip)

 

Contact Us

Patients, caregivers, friends, family and healthcare professionals can count on Novartis Vaccines to answer questions regarding our products and services.

If our search function doesn't find the information that you're looking for, contact us and we'll start finding your answers right away.

Phone

877-NV-DIRECT  (1-877-683-4732)
Customer Service Representative: Monday - Friday, 8:00am - 8:00pm EDT/EST
Medical Communications: Monday - Friday, 9:00am - 5:30pm EDT/EST

In case of medical emergency, please contact your physician immediately. Hours of operation may vary during U.S. holidays. For medically related questions, please email vaccinesinfo.us@novartis.com

Mail

Novartis Vaccines
Medical Communications-US
350 Massachusetts Avenue
Cambridge, MA 02139
United States of America

Upon receipt of your letter, we will mail a reply to you within 2 business days. Please allow for US postal service turnaround time. Response times may vary during U.S. holiday periods.

Indication

Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 2 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.

Important Safety Information

You should not receive Menveo if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as Menveo.

Side effects to Menveo include pain at the injection site, headache, muscle pain, fatigue, nausea, and fainting. Sometimes fainting is accompanied by falling with injury. Other side effects may occur.

Following vaccination with another US-licensed meningococcal conjugate vaccine, an evaluation of postmarketing adverse events suggested a potential for increased risk of Guillain-Barré Syndrome (GBS). There is not enough information to evaluate if a risk of GBS exists following administration of Menveo.

Tell your doctor if you are pregnant or planning to get pregnant.

Vaccination with Menveo may not protect all individuals.

For more information about Menveo, talk to your health-care professional.

Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.

Menveo.com Exit Notice

You are now leaving the Menveo.com site and moving to an external website independently operated and not managed by Novartis Vaccines and Diagnostics Inc. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or, click OK to continue.

OKCancel